
Topic
Coverage Access
Formulary tiers, utilization management, patient support, and the access layer GoodRx and drug labels do not explain.

Pricing & Access· June 6, 2026 · 10 min read
By Ran Chen#GLP-1#Medicaid#Prior Authorization

Pricing & Access· June 6, 2026 · 12 min read
Medi-Cal GLP-1 coverage: what changed January 2026, what stays covered, and PA pathways
By Ran Chen#GLP-1#Medicaid#Prior Authorization

Policy· June 6, 2026 · 12 min read
Medicaid GLP-1 coverage state by state: the 2026 landscape
By Ran Chen#GLP-1#Medicaid#Payer Coverage

Pricing & Access· June 6, 2026 · 10 min read
OptumRx GLP-1 coverage: formulary tiers, PA criteria, and 2026 UM rules
By Ran Chen#GLP-1#OptumRx#Prior Authorization

Pricing & Access· June 6, 2026 · 11 min read
TRICARE GLP-1 coverage: plan breakdown, PA criteria, and August 2025 change
By Ran Chen#GLP-1#TRICARE#Prior Authorization

Pricing & Access· June 6, 2026 · 11 min read
UMR GLP-1 coverage: PA criteria, formulary tiers, and employer-plan rules for 2026
By Ran Chen#GLP-1#UMR#Prior Authorization

Pricing & Access· June 6, 2026 · 12 min read
UnitedHealthcare GLP-1 coverage: PA criteria, reauth rules, and plan variations
By Ran Chen#GLP-1#UnitedHealthcare#UHC

Pricing & Access· June 6, 2026 · 11 min read
VA GLP-1 coverage: formulary status, non-formulary Wegovy criteria, and CHAMPVA rules
By Ran Chen#GLP-1#Veterans Affairs#Prior Authorization

Pipeline· June 5, 2026 · 11 min read
Atacicept PDUFA preview: first dual BAFF/APRIL therapy approaches IgA nephropathy decision
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence

Pipeline· June 5, 2026 · 12 min read
Gedatolisib PDUFA preview: pan-PI3K/mTOR inhibitor targets HR+/HER2– breast cancer gap
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence